Routine board appointment with no earnings, guidance, or strategic pivot. No actionable trading signal, monitor next quarterly earnings for any operational updates.
ALKS drugs
ALKS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 16 $46.07entry
- T+1 · 2mo ago +1.39%α +0.26% · $46.71
- T+5 · 8w ago −8.55%α −11.12% · $42.13
- T+20 · 5w ago −13.76%α −16.94% · $39.73
- T+43 · todayOpen
- T+60 · in 23d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alkermes appointed Anne C. Whitaker as an independent director, expanding the board from 10 to 11 members. Ms. Whitaker is a seasoned biopharmaceutical executive with prior CEO experience and current board seats at ICON plc and Basilea Pharmaceutica. The filing is a routine board appointment with no material financial impact, no financial results, guidance, or strategic changes were disclosed.
Key Facts
- Board expanded from 10 to 11 directors with the appointment of Anne C. Whitaker.
- Ms. Whitaker will receive an initial equity award with an aggregate target value of $600,000, split 50% stock options and 50% RSUs, vesting over three years.
- Ms. Whitaker is an independent director with no prior transactions with the company since January 1, 2025.
- The appointment is effective September 14, 2026, with a term expiring at the 2027 annual general meeting.
Financial Impact
Initial director equity award of $600,000 in aggregate target value, immaterial relative to a $7.7B market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-392527 |
| Document: alks-ex99_1.htm | 0001193125-26-392527 |
| Document: 0001193125-26-392527-index-headers.html | 0001193125-26-392527 |
| Document: 0001193125-26-392527-index.html | 0001193125-26-392527 |
| Document: 0001193125-26-392527.txt | 0001193125-26-392527 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Viewing Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers